Contact
Please use this form to send email to PR contact of this press release:
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
TO:
Please use this form to send email to PR contact of this press release:
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
TO: